ProCE Banner Activity

CE

Equitable Education: Strategies for NPs and PAs to Reduce Healthcare Disparities in Underserved and Underrepresented Patients With Moderate to Severe Atopic Dermatitis

Video

On-demand webcast of expert faculty presentation on strategies to reduce healthcare disparities in patients with moderate to severe atopic dermatitis from underserved and underrepresentated populations for advanced practice providers. 

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: October 29, 2024

Expiration: October 28, 2025

Share

Faculty

Terry Faleye

Terry Faleye, MPAS, PA-C

Dermsurgery Associates – Kingwood
Houston, Texas

Victoria Garcia-Albea

Victoria Garcia-Albea, PNP, DCNP

Director, Lahey Dermatology Nurse Practitioner Training Program
Lahey Dermatology
Burlington, Massachusetts

Peter Lio

Peter Lio, MD, FAAD

Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Founding Partner, Medical Dermatology Associates of Chicago
Chicago, Illinois

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals

Sanofi

Target Audience

This program is intended for nurse practitioners and physician associates who care for underserved/underrepresented patients with moderate to severe atopic dermatitis.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Atopic Dermatitis.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Integrate effective strategies for diagnosing moderate to severe atopic dermatitis in patients with skin of color through physical examination and a thorough medical history

  • Implement strategies that are aimed at providing optimal management of moderate to severe atopic dermatitis to patients affected by healthcare disparities in underrepresented and underserved populations

  • Evaluate strategies for addressing patient-level and practice-level disparities in care among patients with moderate to severe atopic dermatitis

Disclosure

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Terry Faleye, MPAS, PA-C

Dermsurgery Associates – Kingwood
Houston, Texas

Terry Faleye, MPAS, PA-C: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, DermaVant, Janssen, Regeneron/Sanofi, Sun Pharma, UCB.

Victoria Garcia-Albea, PNP, DCNP

Director, Lahey Dermatology Nurse Practitioner Training Program
Lahey Dermatology
Burlington, Massachusetts

Victoria Garcia-Albea, PNP, DCNP: consultant/advisor/speaker: Sanofi Genzyme, Sun Pharma.

Peter Lio, MD, FAAD

Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Founding Partner, Medical Dermatology Associates of Chicago
Chicago, Illinois

Peter Lio, MD, FAAD: consultant/advisor/speaker: AbbVie, Almirall, Alphyn Biologics, Amyris, Arcutis, Aslan, Boston Skin Science, Bristol Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Bioscience, Dermavant, Galderma, Hyphens, Inctye, Janssen, Johnson & Johnson, Kimberly Clark, La Roche-Posay/L’Oreal, LEO Pharma, Lilly, Lipidor, L’Oreal, Merck, Micreos, MyOR Diagnostics, ParentMD, Pelthos Therapeutics, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Sonica, Soteri Skin, Suneco Technologies, Theraplex, UCB, Unilever, Verdant Scientific, Verrica, Yobee Care; patent beneficiary: Theraplex AIM; individual publicly traded stock/stock options: Alphyn Labs, Codex Labs, Concerto Biosci, Soteri Skin, Suneco, Verdant, Yobee Care.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 29, 2024, through October 28, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1.0 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until October 28, 2025. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.